Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF;Velocidad de recuperacion de neutrofilos y efectos secondarios adversos en pacientes con leucemia aguda tratados con quimioterapia intensiva y G-CSF o CM-CSF concomitante

Revista de Investigacion Clinica

Volumn 51, Issue 2, 1999, Pages 77-80

  Alvarado Ibarra, Martha Leticia ^a   Borbolla Escoboza, José Rafael ^a,b   López Hernández, Manuel Antonio ^a   González Avante, C Mauricio ^a   DeDiego FloresChapa, José ^a   Trueba Christy, Elvira ^a   Anaya Cuellar, Irene ^a  

^a Ctro Medico Nac 20 de Noviembre   (Mexico)

^b NONE   (Mexico)

Author keywords

Chemotherapy; Hematopoietic growth factor; Leukemia

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; NEUTROPHIL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; FEMALE; FEVER; FILGRASTIM; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; LEUKEMIA; MALE; METHOTREXATE; MIDDLE AGED; MITOXANTRONE; NAUSEA; NEUTROPENIA; NEUTROPHILS; PAIN; PREDNISONE; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 2442742398     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Delwel R, Salem M, Pellens C, Dorssers L, Wagemaker C, Clark S et al. Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. Blood 1988; 72: 1944-9.
2. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T et al. Effect of granulocyte colony-stimulating factor after intensive chemotherapy in relapsed or refractory acute leukemia. N Eng J Med 1990; 323: 871-7.
3. Goodnough NT, Anderson KC, Kurtz S, Lane TA, Pisciotto PT, Sayer MH et al. Indications and guidelines for the use of hematopoietic growth factors. Transfusion 1993; 33: 944-9.
4. Calderwood S, Romeyer F, Blanchette V, Chan H, Doyle J, Greenberg M et al. Concurrent RhGM-CSF does not offset myelosupression from intensive chemotherapy a randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am J Hematol 1994; 47: 27-34.
5. Kantarjian HM, Estey EH, O'Brien S, Anaissie E, Beran M, Ríos MB et al. Intensive, chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 1992; 79: 876-81.
6. Welte K, Mempel K, Reiter A, Yakisan E, Odenwald E, Pfetsch M et al. A randomized phase III trial of recombinant human granulocyte colony-stimulating factor (r-metHuG-GSF) in childhood high risk acute lymphoblastic leukemia. Blood 1993; 82: 194a.
7. Ottman OG, Hoelzer D. Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia?. Leukemia 1996; 10(suppl 2): S52.
8. Witz F, Harousseau JL, Sadoun D. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Hematol Blood Trans 1997; 40: 852-7.
9. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al. Results of a randomized double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710-8.
10. Buchner T, Hiddemann W, Worman B, Zuhlsdorf M, Rottmann R, Innig G et al. Hematopoietic growth factors in acute myeloid leukemia: Supportive and priming effects. Semin Oncol 1997; 24: 124-9.
11. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beram M et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246-55.
12. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al. A controlled study of recombinant human granulocyte colony stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332: 1678-85.
13. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Lee EJ et al. Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671-7.
14. Zittoun R, Suciu S, Mandelli F, De Witte T, Thaler J, Stryckmans P et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by then European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150-7.
15. Morstyn G, Campbell L, Leishke G, Layton JE, Maher D, O'Connor M et al. Treatment of chemotherapy induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989; 7: 1554-9.
16. Seward WP. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 1993; 342: 153-8.
17. Stewart WP, Scarffe JH, Austin R, Bonnem E, Thatcher N, Morgenstern G et al. Recombinant human granulocyte-macrophage, colony-stimulating factor (rhGM-CSF) given a daily short infusions-a phase I dose-toxicity study. Br J Cancer 1989; 59: 142-7.
18. Santillana S, Gomez H, Casanova L, Kahatt C, Valdivia S, Otero J et al. Age-related toxicity pattern of granulocyte-macrophage colony stimulating factor (GM-CSF) in aggressive malignant lymphoma patients (pts) treated with chemotherapy (CT). Blood 1995; 86: 703a.
19. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994; 83: 2086-92.
20. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy for newly diagnosed acute myelogenous leukemia or myelodysplasia syndromes: Comparison with fludarabine plus cytarabine without granulocyte-colony stimulating factor. J Clin Oncol 1994; 12: 671-7.